HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.0184
Abstract: Importance Glioblastoma is an incurable tumor, and the therapeutic options for patients are limited. Objective To determine whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) is safe and whether… read more here.
Keywords: her2 car; glioblastoma; her2; virus ... See more keywords
Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer.
Sign Up to like & getrecommendations! Published in 2018 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2017.3323
Abstract: TheAmericanSocietyforClinicalPathologytogetherwith the College of American Pathologists, the Association for Molecular Pathology, and the American Society of Clinical Oncology have recently published a guideline for biomarkers in the evaluation of colorectal cancer (CRC).1 In this article… read more here.
Keywords: biomarker; cancer; metastatic crc; her2 ... See more keywords
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.6012
Abstract: Importance The 2013/2014 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) guidelines for HER2 testing by fluorescence in situ hybridization (FISH) designated an “equivocal” category (average HER2 copies per tumor cell ≥4-6… read more here.
Keywords: her2 equivocal; alternative control; breast; breast cancers ... See more keywords
Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2-positive cancers.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13419
Abstract: Human epidermal growth factor receptor 2 (ErbB2/HER2) is a tyrosine kinase receptor that is overexpressed in 25% of primary human breast cancers, as well as in multiple other cancers. HER2-targeted therapies improved progression-free and overall… read more here.
Keywords: ebselen oxide; oxide derivatives; her2; new allosteric ... See more keywords
Precision Cuproptosis Activation via HER2‐Targeted Bimetallic MOF Nanoreactors Breaks Metabolic Adaptation in Aggressive Breast Cancers
Sign Up to like & getrecommendations! Published in 2025 at "Advanced Functional Materials"
DOI: 10.1002/adfm.202512905
Abstract: Tumor heterogeneity and the single‐pathway inhibition mechanisms of trastuzumab represent major contributors to treatment failure in human epidermal growth factor receptor 2‐positive (HER2+) breast cancer. Cuproptosis, a promising copper‐dependent cell death mechanism, remains clinically constrained… read more here.
Keywords: cancer; breast; cuproptosis; copper ... See more keywords
Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments
Sign Up to like & getrecommendations! Published in 2024 at "Advanced Science"
DOI: 10.1002/advs.202403253
Abstract: Trastuzumab (TZM) is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) and is clinically used for the treatment of HER2‐positive breast tumors. However, the tumor microenvironment can limit the access… read more here.
Keywords: varying tumor; tzm her2; delivery; tumor microenvironments ... See more keywords
Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Communications"
DOI: 10.1002/cac2.12577
Abstract: Disitamab vedotin (DV; RC48‐ADC) is an antibody‐drug conjugate comprising a human epidermal growth factor receptor 2 (HER2)‐directed antibody, linker and monomethyl auristatin E. Preclinical studies have shown that DV demonstrated potent antitumor activity in preclinical… read more here.
Keywords: cancer; drug conjugate; her2; antibody drug ... See more keywords
Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Communications"
DOI: 10.1002/cac2.12662
Abstract: The standard first‐line treatment for human epidermal growth factor receptor 2 (HER2)‐positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti‐HER2 bispecific antibody,… read more here.
Keywords: cancer; breast cancer; her2; her2 positive ... See more keywords
Enhanced humoral immunity in breast cancer patients with high serum concentration of anti‐HER2 autoantibody
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3742
Abstract: Humoral immunity plays a substantial role in the suppression of breast cancer. We have revealed that a high serum concentration of anti‐HER2 autoantibody (HER2‐AAb) is associated with favorable outcomes in patients with invasive breast cancer.… read more here.
Keywords: her2 aab; her2; breast cancer;
Intratumoral heterogeneity, treatment response, and survival outcome of ER‐positive HER2‐positive breast cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5788
Abstract: ER+HER2+ breast cancer requires most types of systemic therapies perioperatively. However, treatment resistance is often experienced. The current study investigated the predictive and prognostic value of intratumoral heterogeneity and conventional clinicopathological factors in patients with… read more here.
Keywords: her2; breast cancer; treatment; cancer ... See more keywords
Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5817
Abstract: Loss of HER2 “positivity” can occur in patients with residual disease after neoadjuvant treatment, but the incidence of HER2‐positivity loss after neoadjuvant dual HER2‐targeted treatment plus chemotherapy, the current standard‐of‐care for most early stage HER2‐positive… read more here.
Keywords: dual her2; her2; her2 positivity; positivity loss ... See more keywords